Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Operations (Unaudited)

v3.20.2
Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Expenses    
Research and development $ 1,357 $ 721
General and administrative 1,534 914
Merger costs 500  
In-process research and development 16,094  
Operating Expenses 19,485 1,635
Other (income) loss    
Foreign exchange loss (1)  
Amortization of deferred loan costs 27  
Interest expense 8  
Interest income (1) (29)
Other loss (income) 33 (29)
Net loss for the period 19,518 1,606
Computation of basic loss per share    
Net loss for the period 19,518 1,606
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance 3,181  
Series A Preferred cash dividend 2 2
Series B Preferred stock dividend 5 2
Net loss for the period attributable to common stockholders $ 22,706 $ 1,610
Basic and fully diluted loss per share $ 1.33 $ 0.21
Basic and fully diluted weighted average number of shares 17,106,000 7,539,000